I'm curious as to whether Neuren has protected the priority review voucher that would come with an approval of NNZ-2591.
If Acadia was to get the first NNZ-2591 approval - Fragile X through the FDA for example - would they be entitled to the voucher instead of Neuren?
Pipeline-in-a-drug, page-49
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.30 |
Change
0.170(1.12%) |
Mkt cap ! $1.933B | |||
| Open | High | Low | Value | Volume |
| $15.06 | $15.32 | $14.95 | $1.294M | 85.63K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 539 | $15.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.31 | 115 | 4 |
View Market Depth
| Last trade - 12.04pm 02/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |